Indianapolis, IN, United States of America

Stephen W Kaldor

This inventor holds 30 USPTO granted patents and 10 published patent applications, plus 5 CIPO patents, primarily in HIV Protease Inhibitors. Top assignees: Eli Lilly and Company, Agouron Pharmaceuticals, Inc.. Active years: 1995-2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Stephen W Kaldor. Retrieved from https://idiyas.com/inventor/stephen-w-kaldor-d54nf5ea

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 10)

% Patents Active = 93.3

CIPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 4.6

ph-index = 9

Forward Citations = 285(Granted Patents)

Company Filing History:

20 out of 4,514

Eli Lilly and Company

patents

10 out of 174

Agouron Pharmaceuticals, Inc.

patents

Years Active: 1995-2004

Loading Chart...

Areas of Expertise:

HIV Protease Inhibitors

Non-Peptidyl Antagonists

Vasopressin V1A

Tachykinin Receptor Antagonists

Anti-Viral Method

Pharmaceutical Compositions

Carbodiimide Coupling Reagent

Serotonin 5-HT1F Agonists

Retroviral Protease Inhibitors

Anti-Picornaviral Agents

Intermediates for Inhibitors

5-Substituted Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6693199 - Method of making HIV protease inhibitors (2004-02-17),

2. 6610680 - Non-peptidyl vasopressin V1A antagonists (2003-08-26),

3. 6525215 - HIV protease inhibitors (2003-02-25),

4. 6521611 - Non-peptidyl vasopressin V1a antagonists (2003-02-18),

5. 6358994 - 2-acylaminopropanamines as tachykinin receptor antagonists (2002-03-19),

6. 6339094 - 2-acylaminopropanamines as tachykinin receptor antagonists (2002-01-15),

7. 6271235 - HIV protease inhibitors (2001-08-07),

8. 6204260 - Non-peptidyl vasopressin V1a antagonists (2001-03-20),

9. 6162812 - Pharmaceutical compositions containing HIV protease inhibitors and (2000-12-19),

10. 6126932 - Polymer bound carbodiimide coupling reagent (2000-10-03),

11. 6060484 - Anti-viral method (2000-05-09),

12. 5998630 - Carbodiimide coupling reagent (1999-12-07),

13. 5962474 - 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and (1999-10-05),

14. 5952343 - HIV protease inhibitors (1999-09-14),

15. 5942536 - N-�2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT.sub.1F (1999-08-24),

Title: Stephen W. Kaldor: A Pioneer in Pharmaceutical Innovations

Introduction

Stephen W. Kaldor is a notable inventor based in Indianapolis, IN, with an impressive portfolio of 30 patents to his name. His work primarily focuses on developing innovative solutions within the pharmaceutical industry, which has had a significant impact on health and wellness.

Latest Patents

Among his most recent patents are groundbreaking intellectual properties such as a method of making HIV protease inhibitors and non-peptidyl vasopressin V1A antagonists. These inventions exhibit Kaldor's commitment to addressing critical medical challenges and enhancing therapeutic options.

Career Highlights

Stephen has had a distinguished career, working with prominent companies such as Eli Lilly and Company and Agouron Pharmaceuticals, Inc. During his time at these organizations, he was heavily involved in research and development efforts that brought innovative pharmaceutical products to market, showcasing his expertise in drug formulation and design.

Collaborations

Throughout his career, Stephen Kaldor has collaborated with esteemed colleagues, including James E. Fritz and Bruce Anthony Dressman. These partnerships have contributed to the advancement of numerous projects and have fostered a collaborative spirit in the pursuit of innovation in the pharmaceutical field.

Conclusion

Stephen W. Kaldor's contributions to the field of pharmaceuticals, highlighted by his 30 patents and collaborations with industry-leading professionals, mark him as a pioneer in innovation. His work continues to influence the way healthcare challenges are approached, making a meaningful difference in the lives of many.

Profile summary based on public USPTO records.